FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
Search
New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
Tackling Health Disparities and Inequities for Women With Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
FDA accepts sNDA for children/adolescents with fibrosing ILD
U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease
Business Resource Groups at Boehringer Ingelheim
Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US
Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
FDA Approves Jardiance® (empaglifozin) for T2D | BI US
Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes
New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
New Swine Vaccine Combination Released | Boehringer Ingelheim US
Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.
Jardiance® (empagliflozin) analysis reinforces established safety profile
Jardiance® (empagliflozin) analysis reinforces established safety profile
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Planting Trees to Help Care for the Environment
Planting Trees to Help Care for the Environment
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Onboarding
Onboarding
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program